Thursday 16 October, 2025
Objectives: The pharmacokinetics of many drugs are said to be predictable. This is often used to imply the ease of dosing…
Read morePoster: Methodology - Covariate/Variability Models
Comparison of common methodologies for accounting for IIV for oral bioavailability in the absence of intravenous data
Thursday 16 October, 2025
Objectives: The oral bioavailability (F) of a drug is the product of the fraction absorbed (Fa), the fraction escaping the…
Read moreEvaluation of stepwise covariate model selection with Bayesian models
Thursday 16 October, 2025
Objectives: Stepwise covariate modeling (SCM) is a commonly used tool for covariate model selection. Traditionally, SCM as implemented in Perl…
Read moreNew micronized formulation does not affect the population pharmacokinetic properties of artemisinin.
Thursday 16 October, 2025
Objectives: Malaria is still a major health problem in the poorest parts of the world. The highly effective first line treatment…
Read moreAging and maturation as a reliability problem: The Weibull distribution and age- and maturation-adjustment functions
Thursday 16 October, 2025
Objectives: In covariate analysis, age is often examined for its relationship with model parameters. An individual’s age is informative for…
Read moreImplicit and efficient handling of missing covariate information using full random effects modelling
Thursday 16 October, 2025
Introduction: Covariates are observable predictors that are included in models to reduce the unexplained variability. The identification and estimation of…
Read moreDose Response Models for Multiple Endpoints: A Simulation Study
Thursday 16 October, 2025
Objectives: There are potential advantages in modeling multiple endpoints simultaneously in a single model fit: 1) perform tests on shared parameters…
Read moreThe population pharmacokinetics of Compound X following single and multiple intravenous infusions, to healthy subjects and subjects following surgery.
Thursday 16 October, 2025
Objectives: The aim of this study was to characterise the pharmacokinetics (PK) of Compound X in healthy subjects and subjects…
Read moreBayesian Variable Selection for high-throughput genetic association analysis in population pharmacokinetics.
Thursday 16 October, 2025
Rational: In population pharmacokinetics (PK), the standard genetic association analysis is a stepwise procedure. We have shown that an integrated…
Read morePopulation approach in high-throughput pharmacogenetics: challenging the maximum likelihood approaches and exploration of a Bayesian alternative
Thursday 16 October, 2025
Context: In a previous study, we have shown that an integrated approach, simultaneously estimating the PK model parameters and the genetic…
Read more